Data from GADD45β Loss Ablates Innate Immunosuppression in Cancer
T-cell exclusion from the tumor microenvironment (TME) is a major barrier to overcoming immune escape. Here, we identify a myeloid-intrinsic mechanism governed by the NF-κB effector molecule GADD45β that restricts tumor-associated inflammation and T-cell trafficking into tumors. In various models of solid cancers refractory to immunotherapies, including hepatocellular carcinoma and ovarian adenocarcinoma, Gadd45b inhibition in myeloid cells restored activation of proinflammatory tumor-associated macrophages (TAM) and intratumoral immune infiltration, thereby diminishing oncogenesis. Our results provide a basis to interpret clinical evidence that elevated expression of GADD45B confers poor clinical outcomes in most human cancers. Furthermore, they suggest a therapeutic target in GADD45β for reprogramming TAM to overcome immunosuppression and T-cell exclusion from the TME.
Significance: These findings define a myeloid-based immune checkpoint that restricts T-cell trafficking into tumors, with potentially important therapeutic implications to generally improve the efficacy of cancer immunotherapy. Cancer Res; 78(5); 1275–92. ©2017 AACR.
CITE THIS COLLECTION
FUNDING
Cancer Research UK
Medical Research Council (MRC) Biomedical Catalyst
Bloodwise project
Associazione Italiana per la Ricerca sul Cancro (AIRC)
MIUR PRIN
MIUR FIRB
SHARE
Usage metrics
Read the peer-reviewed publication

AUTHORS (20)
- DVDaniela VerzellaJBJason BennettMFMariafausta FischiettiATAnil K. ThotakuraCRCamilla RecordatiFPFabio PasqualiniDCDaria CapeceDVDavide VecchiottiDDDaniel D'AndreaBDBarbara Di FrancescoMDMarcella De MaglieFBFederica BegalliLTLaura TornatoreSPSalvatore PapaTLToby LawrenceSFStuart J. ForbesASAntonio SicaEAEdoardo AlesseFZFrancesca ZazzeroniGFGuido Franzoso